EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 120-129

  Barreiros, Ana Paula ^a   Sprinzl, Martin ^a   Rosset, Sylvia ^a   Höhler, Thomas ^a,b   Otto, Gerd ^a   Theobald, Matthias ^c   Galle, Peter R ^a   Strand, Dennis ^a   Strand, Susanne ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b PROSPER HOSPITAL   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apoptosis; CD95; Cytotoxic t lymphocytes; EGF; HBV; HGF; Human hepatocytes

Indexed keywords

BETA1 INTEGRIN; CASPASE 9; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL KILLING; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CELL; LIVER REGENERATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; UPREGULATION; CELL ADHESION; CELL CULTURE; CELL MEMBRANE POTENTIAL; HEPATITIS B VIRUS; IMMUNE SYSTEM; METABOLISM; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; APOPTOSIS; CELL ADHESION; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; IMMUNE SYSTEM; MEMBRANE POTENTIALS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 58149397357     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23921     Document Type: Article

References (41)

1. 1.Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005;34(Suppl 1):S139-42.
2. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81.
3. Protzer U, Schaller H. Immune escape by hepatitis B viruses. Virus Genes 2000;21:27-37.
4. Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol 2002;67:454-7.
5. Mateescu RB, Rimbas M, Voiosu R. The immunopathogenesis of viral hepatitis. Rom J Intern Med 2004;42:59-67.
6. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells-a mechanism of immune evasion? Nat Med 1996;2:1361-7.
7. Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H, Mariani SM, Hack V, Stremmel W, Krammer PH, Galle PR. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998;4: 588-93.
8. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-8.
9. Rudi J, Kuck D, Strand S, von Herbay A, Mariani SM, Krammer PH, Galle PR, Stremmel W. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest 1998;102:1506-14.
10. Ricci-Vitiani L, Conticello C, Zeuner A, De Maria R. CD95/CD95L interactions and their role in autoimmunity. Apoptosis 2000;5:419-24.
11. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3: 409-13.
12. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis 1998;18:141-51.
13. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, Demetris AJ. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology 1998;28:1260-8.
14. von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 1998;58:526-34.
15. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998;91:2875-85.
16. Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, Heid H, Kuball J, Theobald M, Galle PR, Strand D. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004;23:3732-6.
17. Rosen D, Li JH, Keidar S, Markon I, Orda R, Berke G. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1). J Immunol 2000;164:3229-35.
18. Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 2003;171:2402-12.
19. Felzen B, Shilkrut M, Less H, Sarapov I, Maor G, Coleman R, Robinson RB, Berke G, Binah O. Fas (CD95/Apo-1)-mediated damage to ventricular myocytes induced by cytotoxic T lymphocytes from perforin-deficient mice: a major role for inositol 1,4,5-trisphosphate. Circ Res 1998;82:438-50.
20. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446-52.
21. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
22. Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+CTL. J Immunol 2000;164:4941-54.
23. Fausto N. Liver regeneration. J Hepatol 2000;32:19-31.
24. Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T, Shiraki K. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32:796-802.
25. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006;66:3963-6.
26. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005;24:7391-3.
27. Hong F, Nguyen VA, Shen X, Kunos G, Gao B. Rapid activation of protein kinase B/Akt has a key role in antiapoptotic signaling during liver regeneration. Biochem Biophys Res Commun 2000;279:974-9.
28. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 2000;278:G354-66.
29. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261-81.
30. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
31. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999;19:151-9.
32. Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995;21:106-12.
33. Rahman MA, Eid SA, Rahman AA, Nasr G, Morsy TA. Epidermal growth factor in patients with schistosomal and/or viral liver diseases and portal hypertension. J Egypt Soc Parasitol 2000;30:233-13.
34. Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004;39:1182-8.
35. Noji S, Tashiro K, Koyama E, Nohno T, Ohyama K, Taniguchi S, Nakamura T. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situhybridization. Biochem Biophys Res Commun 1990;173:42-7.
36. Skrtic S, Wallenius V, Ekberg S, Brenzel A, Gressner AM, Jansson JO. Hepatocyte-stimulated expression of hepatocyte growth factor (HGF) in cultured rat hepatic stellate cells. J Hepatol 1999;30:115-24.
37. Marti U, Burwen SJ, Jones AL. Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: an update. Hepatology 1989;9:126-38.
38. Noguchi S, Ohba Y, Oka T. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. J Endocrinol 1991;128:425-31.
39. Jones DE, Jr, Tran-Patterson R, Cui DM, Davin D, Estell KP, Miller DM. Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. Am J Physiol 1995;268:G872-8.
40. Lambotte L, Saliez A, Triest S, Maiter D, Baranski A, Barker A, Li B. Effect of sialoadenectomy and epidermal growth factor administration on liver regeneration after partial hepatectomy. Hepatology 1997;25: 607-12.
41. Imado T, Iwasaki T, Kataoka Y, Kuroiwa T, Hara H, Fujimoto J, Sano H. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 2004;104:1542-9.